Lithium protects dopaminergic cells from rotenone toxicity via autophagy enhancement

Citation
Hou, Lingling, Nian Xiong, Ling Liu, Jinsha Huang, Chao Han, Guoxin Zhang, Jie Li, Xiaoyun Xu, Zhicheng Lin, and Tao Wang. 2015. “Lithium protects dopaminergic cells from rotenone toxicity via autophagy enhancement.” BMC Neuroscience 16 (1): 82. doi:10.1186/s12868-015-0222-y. http://dx.doi.org/10.1186/s12868-015-0222-y.

Published Version
doi:10.1186/s12868-015-0222-y

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:23845250

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Background: Parkinson's disease (PD), a chronic and progressive neurodegenerative disease, is manifested as motor symptoms such as tremor, bradykinesia, rigidity and postural instability, as well as non-motor symptoms such as depression, apathy, sleep disorders and erectile dysfunction [1]. The hallmark pathological signs of PD include the degeneration of dopaminergic (DA) neurons in the substantia nigra and the formation of α-synuclein+ protein aggregates which are called Lewy bodies or Lewy neurites in the remaining DA neurons. Although treatments that slow or halt the disease process are currently unavailable, manipulating protein aggregation seems to have great potential for disease-modification [1].

There are two important mechanisms for protein degradation in the mammalian cells, detailed as the autophagy-lysosome pathway (ALP) and the ubiquitin-proteasome system (UPS). Previous studies have demonstrated that dysfunction of these two systems plays vital roles in the progression of PD. Therefore, strategies to manipulate protein homeostasis are expected to be beneficial for PD patients.}

Lithium protects dopaminergic cells from rotenone toxicity via autophagy enhancement

Lingling Hou1†, Nian Xiong2†, Ling Liu2†, Jinsha Huang2, Chao Han2, Guoxin Zhang2, Jie Li2, Xiaoyun Xu2, Zhicheng Lin3 and Tao Wang2*

Abstract

Background: Previous studies have indicated that enhancement of autophagy lysosome pathway may be beneficial for Parkinson’s disease (PD), in which aberrant accumulation of aggregated/misfolded proteins and mitochondrial dysfunction are considered as crucial pathogenesis. Recently, a number of studies have suggested the neuroprotective effects of lithium in models of several neurodegenerative diseases including PD. However, the exact mechanisms underlying this neuroprotection remain unclear. In our study, rotenone-exposed SH-SY5Y cells were used as an in vitro parkinsonian model to assess the autophagy-enhancing effect of lithium and the underlying mechanisms were further investigated.

Results: Similar to the common used autophagy enhancer rapamycin (Rap, 0.2 μM), lithium (LiCl, 10 mM) significantly recovered the shrinkage of SH-SY5Y cells, and alleviated rotenone-induced cell apoptosis, mitochondrial membrane potential reduction and reactive oxygen species accumulation. Furthermore, the protective effects induced by LiCl were partially blocked by the co-treatment of autophagy inhibitors such as 3-methyladenine (3-MA, 10 mM) or chloroquine (CHL, 10 μM). Moreover, 3-MA or CHL suppressed LiCl-induced autophagy in the immunoblot assay. In addition, the co-localization of LC3 and mitochondria and the preservation of mitochondrial function within LiCl-treated cells were observed, confirming that the damaged mitochondria were cleared through autophagy (mitophagy).

Conclusions: These findings suggested that lithium exerted neuroprotection against rotenone-induced injuries partially through the autophagy pathway. Pharmacologically induction of autophagy by lithium may represent a novel therapeutic strategy as a disease-modifier in PD.

Keywords: Lithium, Autophagy, SH-SY5Y Cells, Parkinson’s disease
the pathogenesis of PD [2–5]. The function of UPS is limited by the core volume, and upregulated proteasome activity only leads to non-selective degradation of key short-lived intracellular regulators, resulting in detrimental consequences, such as cancer in the case of tumor suppressor p53 [1]. In contrast, ALP degrades entire organelles such as mitochondria and large membrane proteins which fail to recycle by UPS [4, 6]. Thus, enhancement of autophagy might be a novel strategy for the treatment of protein accumulation-related diseases, such as PD.

The commonly used strategy for inducing autophagy is employing rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR) [7, 8]. Previous studies have revealed that rapamycin exerts neuroprotective effects in several models of neurodegenerative diseases such as Alzheimer’s disease (AD) and PD through autophagy enhancement [9–11]. However, since mTOR plays an important role in regulating a variety of basic cellular processes, long-term use of rapamycin may cause some deleterious consequences, including cell over-growth and proliferation [12]. It is crucial to explore an autophagy enhancer which is safe, clinical-relevant and easy to administrate.

Unlike rapamycin, lithium (LiCl) induces autophagy via an mTOR-independent pathway. By inhibiting the inositol monophosphatase (IMPase), LiCl ultimately results in the reduction of free inositol cellular level [13–16]. A recent study has indicated that LiCl suppressed Aβ pathology by inhibiting the translation of protein in a Drosophila model of AD [17]. Furthermore, LiCl protected against paraquat-induced neurotoxicity by NRF2 activation and miR-34a inhibition in SH-SY5Y cells [18]. Moreover, our previous studies have suggested that LiCl might be neuroprotective in rotenone-induced SH-SY5Y cells and MPTP-lesioned mice though autophagy enhancement [19, 20]. However, another study have indicated that LiCl was unable to alleviate the degeneration of DA neurons induced by 6-OHDA, suggesting that GSK3 was minimally involved in the neurodegeneration [21]. Thus, it remains unclear whether or not LiCl exerts neuroprotective effects and by which pathway LiCl is involved in the neuroprotection.

In this study, rotenone-exposed SH-SY5Y cells were used as an in vitro model of PD, and cell viability, activation of apoptosis, oxidative stress and mitochondrial dysfunction were assessed respectively [3, 22, 23, 24]. Rapamycin was used as a positive control for induction of autophagy. The neuroprotective effects of LiCl on the rotenone-induced cellular model as well as the underlying mechanisms were further explored.

Results

LiCl increased cell viability upon rotenone exposure in SH-SY5Y cells

We first examined whether or not LiCl affected cell survival under normal culture condition. MTT analysis indicated that in the range of 1 mM to 15 mM, LiCl did not significantly affect the viability of SH-SY5Y cells, while the concentration of 50 mM LiCl directly caused 48.3 ± 5.37 % reduction of MTT absorbance. When treated with rotenone for 24 h, rotenone decreased cell viability by 67.56 % compared with control group, and by 37.46, 32.61, 18.32, 13.68, 23.94 and 41.21 % in LiCl2 + Rot, LiCl4 + Rot, LiCl8 + Rot, LiCl10 + Rot, LiCl15 + Rot and LiCl50 + Rot groups, respectively (Fig. 1b). LiCl with a dose range from 2 mM to 50 mM could alleviate rotenone-induced cell death. Moreover, the most significant cytoprotection of LiCl was observed at the concentration of 10 mM (Fig. 1b). Therefore, we chose the concentration of 10 mM for the subsequent tests.

LiCl prevented from rotenone-induced cell injury

First, LiCl-induced neuroprotection was revealed by cell morphology. SH-SY5Y cells under normal culture condition grew into a neuron-like phenotype with extended neuritis. Exposure to rotenone (200 nM) for 24 h resulted in shortening of neurites and shrinking of the cell bodies, which was inhibited by rapamycin or LiCl pretreatment (Fig. 2a). However, the rehabilitative effect of LiCl was partially blocked when cells were co-treatment with the autophagy inhibitors 3-MA or CHL. The MTT assay indicated that rotenone significantly decreased cell viability by ~60 %, while pretreatment with rapamycin or LiCl significantly attenuated the toxic effects induced by rotenone. (Figure 2b). Such rescue of cell viability was partially attenuated by simultaneously pretreatment of 3-MA or CHL. Similar results were observed from cell apoptosis analysis (Fig. 3a). Rotenone exposure led to an increase of cell apoptosis, which was discounted by LiCl or rapamycin pretreatment, while the protective effect of LiCl was partially weakened by 3-MA or CHL, suggesting that the neuroprotective effect of LiCl may be related to autophagy induction (Fig. 3a).

LiCl protected against rotenone-induced mitochondrial dysfunction

The SH-SY5Y cells in negative control showed accumulation of red fluorescence and extended neurites, while rotenone exposure led to reduced red fluorescence with condensed nuclei and cell shrinkage, indicating a collapse of MMP with exposure to rotenone (Fig. 3c). The reduction in MMP meant a lower capacity to produce ATP.
Then the cells pretreated with LiCl significantly inhibited the decrease of fluorescence intensity, indicating that LiCl prevented rotenone-induced mitochondrial injury. In one hand, mitochondrial dysfunction triggered ROS formation, on the other hand, accumulated ROS could in turn cause oxidative damage of mitochondria. To confirm the neuroprotective effect of LiCl on mitochondria, we measured the levels of ROS in different groups. Rotenone evoked obvious production of ROS, and LiCl indeed alleviated the overgeneration of ROS. However, this protective effect of LiCl was partially attenuated when cells were simultaneously pretreated with 3-MA or CHL (Fig. 3b). In addition, pretreatment of cells with CHL resulted in a higher level of ROS release than the rotenone group, indicating that CHL increased cellular vulnerability to rotenone toxicity and mitochondrial dysfunction.

**LiCl enhanced autophagy in SH-SY5Y cells**

In immunoblot assay, the ratio of LC3-II/I with LiCl pretreatment was increased by ~84% when compared to the vehicle control, similar tendency to that of the rapamycin, while the ratio was slightly decreased with co-treatment of LiCl and 3-MA. LC3 expression was highest in the group with co-treatment of LiCl and CHL. By disrupting the pH of acidic vesicles, CHL prevented the fusion process of lysosomes and autophagosomes, and ultimately elevated the cellular burden of autophagosome accumulation [25]. Thus, the accumulation of LC3-II, a classic marker of autophagosome, suggested either that autophagy has been stimulated and/or that the maturation of autophagosomes has been blocked (in the case of the addition of CHL) [26]. Our immunoblot assay indicated that autophagy was up-regulated during LiCl or rapamycin exposure, and such induction of autophagy was attenuated when cells were treated with 3-MA or CHL simultaneously (Fig. 4), suggesting that the protective effect of LiCl was related to the induction of autophagy.

**Damaged mitochondria were eliminated via autophagy**

To detect the association between autophagy induction and the restored mitochondrial function, further immunostaining analysis without rotenone exposure was performed. The results showed that LiCl treatment contributed to a punctuate pattern of LC3 fluorescence in the cytoplasm of SH-SY5Y cells, while it led to a diffuse distribution of LC3 in the absence of LiCl. Additionally, this effect could be partially attenuated by 3-MA or CHL co-treatment (Fig. 5). As shown in the Fig. 5r, there is no statistical difference between these groups regarding the normalized MitoTracker Red fluorescence in the cytoplasm. However, 3-MA or CHL co-treatment significantly reduced the LC3 aggregation induced by LiCl (Fig. 5q). Co-localization of MitoTracker Red and LC3 indicated that the turnover of mitochondria might be within autophagolysosomes.

**Discussion**

As a mood stabilizer, LiCl is traditionally used to treat bipolar disorder [27]. Recent research has focused on its neuroprotective potential and regarded it as a candidate agent for disease-modifying therapy in several neurodegenerative diseases [28–30]. The neuroprotective effect of LiCl may rely on autophagy induction. In our study, human SH-SY5Y cells exposed to rotenone were used...
as an in vitro model of PD to explore the effects of LiCl on rotenone neurotoxicity and its underlying mechanisms. These findings indicated that LiCl could attenuate cell apoptosis, inhibit ROS production and MMP decrease induced by rotenone. Moreover, the protective effects were partially blocked upon pretreatment with autophagy inhibitors such as 3-MA or CHL.

Compared with control group, the ratio of LC3-II/I was elevated by LiCl treatment, showing that LiCl induced autophagy in SH-SYSY cells. However, this autophagy-enhancing effect was partially blocked by 3-MA, a widely used inhibitor of autophagy. As CHL could enhance the cellular burden of autophagosomes which were manifested as the accumulation of LC3-II protein, the increased ratio of LC3-II/I by chloroquine treatment indicated that the maturation of autophagosomes has been blocked, representing an inhibition of the autophagy flux [25].

As a mitochondrial complex I inhibitor, rotenone is extensively used for modelling PD in recent years. In this study, rotenone induced mitochondrial dysfunction as evidenced by the increased production of ROS and the decreased MMP, which may lead to the activation of the mitochondrial apoptotic pathway [31–33]. Mitochondria have been proposed as an important link among risk factors, and eliminating injured mitochondria would be
critical to prevent cells from a series of pro-apoptotic cellular responses. Autophagy is the only process by which organelles such as mitochondria can be degraded. Previous studies indicated that inhibited autophagy was accompanied by accumulated mitochondrial mass [34–36]. Thus, we hypothesized that pretreatment with autophagy-enhancing agents like LiCl might be able to reduce mitochondrial load. As expected, LiCl reduced rotenone-induced apoptosis, ROS production and MMP reduction, exerting similar neuroprotective

![Figure 3](image_url)

**Fig. 3** Lithium attenuated rotenone-induced dysfunction of mitochondria. Cells were pretreated with autophagy-related drugs for 24 h followed by rotenone exposure for another 24 h. The rate of cell apoptosis was measured by Annexin-V/PI staining (**a**) and the fluorescence intensity of DCFH was measured by flow cytometry in all groups (**b**). MitoTracker red CMXRos at a final concentration of 500 nM was used to visualize the mitochondrial transmembrane potential (**c**) and the relative fluorescence intensity was expressed (**d**). *P < 0.05 as compared with Con group; **P < 0.05 versus Rot alone, ***P < 0.05 as compared with LiCl + Rot group; #P < 0.05 as compared with LiCl + Rot group (n = 6 in each group)
effects to another autophagy enhancer rapamycin. To further investigate whether the neuroprotection of LiCl was autophagy-dependent, two chemical suppressors of autophagy 3-MA and CHL were used. The converse results were observed in cells treated simultaneously with 3-MA or CHL, corresponding to the reduced ratio of LC3II/I which suggested that the protective effect of LiCl could be partially blocked as autophagy was inhibited. Then we observed that the mitochondria fluorescence was well merged with the LC3 fluorescence in the cytoplasm of LiCl-treated cells when compared to those treated with autophagy inhibitors or vehicle control. This further supported an elimination of mitochondria via autophagy. As the sole known mechanism for mitochondrial turnover, autophagy serves to preserve the balance between organelle biogenesis and their clearance, and engages in cross-talk with mitochondria and oxidative stress [37].

Our study have indicated that LiCl alleviated rotenone-induced changes in mitochondrial complex I function, cell death and changes to DNA methylation and hydroxymethylation [39]. These findings let us have a more balanced view on the effects of lithium. Since lithium is known to pass the blood–brain barrier and has already been approved by FDA for decades for the treatment of bipolar disorder [40], we could reasonably speculate that by inducing autophagy, lithium may have great potential as a novel therapy for PD, although the possibility requires further investigation.

Conclusions
Taken together, these findings indicated that lithium was able to attenuate cell apoptosis, inhibit ROS production and MMP decrease induced by rotenone in SH-SY5Y. Moreover, autophagy enhancement was involved in this neuroprotection as the effects of lithium were partially blocked upon pretreatment with autophagy inhibitors. Pharmacologically induction of autophagy by lithium may raise a new hope for novel disease-modifying strategies in PD.

Methods
Cell culture and treatment
Human neuroblastoma SH-SY5Y cells (ATCC, Manassas, VA, USA) were cultured in DMEM/F12 medium (Invitrogen, Carlsbad, CA, USA) at 37 °C with 5 % CO2 and 95 % air (v/v). The growth medium was supplemented with 10 % fetal bovine serum (Invitrogen). Rotenone (Sigma-Aldrich, St. Louis, MO, USA) and rapamycin (Sigma-Aldrich) were dissolved in dimethyl sulfoxide (DMSO) before diluted with the culture medium, and the final concentration of DMSO per well was less than 0.2 %. 3-methyladenine (3-MA) (Sigma-Aldrich) was dissolved by heating in ddH2O, while LiCl and chloroquine (CHL) were dissolved in phosphate buffered solution (PBS) before dilution with the culture medium. PBS and DMSO were added to the culture medium in negative control group (PBS for 24 h following DMSO for another 24 h, “Con-group”). The final concentrations of Rap [20, 41], LiCl [20, 42], 3-MA and Chl [20, 43] were 0.2 μM, 1–50 mM, 10 mM and 10 μM, respectively. Rotenone (200 nM) was given for 24 h to induce cell damage. For MTT assay, apoptosis analysis, mitochondrial membrane potential (MMP) and reactive oxygen species (ROS) detection, SH-SY5Y cells were pretreated with vehicle (PBS), Rap, LiCl, LiCl + 3-MA, LiCl + CHL, 3-MA, CHL, respectively, for 24 h, and then rotenone for another 24 h. For assessing microtubule associated protein 1 light chain 3 (LC3) expression in immunostaining and immunoblotting, the cells were only treated with vehicle, Rap, LiCl, LiCl + 3-MA, LiCl + CHL, 3-MA, CHL, respectively, for 24 h.
Fig. 5 Lithium promoted degradation of mitochondria via autophagy. Cells exposed to lithium with or without autophagy inhibitors were incubated with anti-LC3 antibody (1:100) and MitoTracker Red to visualize the co-localization (yellow immunofluorescence) of LC3 (a–d) and mitochondria (e–h) in SH-SY5Y cells at ×400 magnifications under a confocal fluorescence microscope, and the nuclei were stained by DAPI (i–l). The co-localization of autophagosomes and mitochondria was marked using white arrows (m–p). The relative intensity of LC3 (q) and mitochondria were expressed (r). *P < 0.05 as compared with Con group; **P < 0.05 as compared with LiCl + Rot group; ##P < 0.05 as compared with LiCl + Rot group (n = 6 in each group).
**Measurement of cell viability**

Cell viability was detected in MTT assay by a microplate reader (Bio-Rad, Hercules, CA, USA) [22, 44, 45]. Briefly, SH-SY5Y cells were seeded at a density of $1 \times 10^4$ cells per well in 96-well plates. When exposed to different treatments for the indicated times duration, 20 μL of MTT solution (5 mg/mL, Sigma-Aldrich) were added to each well for 4 h to allow the formation of purple formazan crystal. Then, 100 μL of the solubilization reagent was added into each well and spectrophotometrically measured for absorption at $\lambda$ 570 nm.

**Apoptosis analysis**

The FITC-conjugated Annexin V (Annexin V, Sigma-Aldrich) and propidium iodide (PI, Sigma-Aldrich) double-staining followed by flow cytometry (BD, Franklin Lakes, NJ, USA) assessment was employed to analyze the rates of cell apoptosis [22, 44, 45]. Cultivated terminations, $2 \times 10^6$ cells were harvested with 0.25 % trypsin and washed with PBS, and then incubated with Annexin V-FITC (apoptosis detection kit, Sigma-Aldrich) and 20 μg/mL PI (10 μL) for 10 min at 37 °C in the darkness. Then FITC and PI signals were measured with a BD-LSR flow cytometer using the CellQuest software. Data were analyzed by FSC express version 3.0 (De Novo Software, Los Angeles, CA, USA). The apoptosis rate $= \frac{[\text{Annexin V}(+)\text{PI}(+)\text{cells} + \text{Annexin V}(+)\text{PI}(-)\text{cells}]}{\text{total cell} \times 100 \%}.$

**Measurement of reactive oxygen species**

Fluorescent probe 2,7-dichlorofluorescein diacetate (H$_2$DCFDA) was used to measure the intracellular ROS [22, 44, 45]. The generation of dichlorofluorescein (DCF), an oxidized form of H$_2$DCFDA, is proportional to intracellular ROS levels. At the termination of medication, cells were harvested, resuspended in PBS and immediately incubated with 10 μM H$_2$DCFDA (Sigma-Aldrich) for 30 min at 37 °C in the darkness. After washed, the samples were detected by a FACScan flow Cytometer (BD). Data were analyzed by FSC express version 3.0 (De Novo Software, Los Angeles, CA, USA).

**Detection of mitochondrial membrane potential**

Since MitoTracker probe could pass through the plasma membrane and accumulate in mitochondria [22, 46], assessment of MMP was performed using MitoTracker Red CMXRos (Invitrogen). After harvested and resuspended with PBS, cells were cultured with MitoTracker Red CMXRos (500 nM) for 30 min at 37 °C in the darkness, washed with PBS twice and then the nuclei were stained with DAPI (Invitrogen). The MMP level was visualized quantitatively as red fluorescence, while the DNA could be simultaneously observed as blue fluorescence.

**Autophagy detection in immunoblotting analysis**

Autophagy level was detected by a specific marker protein, the autophagosomal membrane form of microtubule-associated protein 1 light chain 3 (LC3) [5], which has two forms, LC3-I (18 KD, a cytoplasmic form) and LC3-II (16 KD, a cleavage form). The conversion of LC3-I into LC3-II (LC3-II level compared to LC3-I level) was indicative of autophagic activity. Higher ratio of LC3-II/LC3-I means higher autophagic activity. After harvested and washed by cold PBS, cells were directly lysed in 100 mL of 2× SDS sample buffer containing protease inhibitors and boiled for 5 min [22, 44, 45]. Then total protein concentration was determined by a BCA kit (Pierce, Rockford, IL, USA). Equal amounts of proteins (40 mg) were separated by SDS–polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane (Pierce). The membranes were then washed three times with PBS, blocked with 5 % dry milk in Tris-buffered saline for 45 min and incubated with primary antibodies directed against LC3 (1: 1000) and β-actin (Santa Cruz, Santa Cruz, CA, USA) overnight at 4 °C. Following three 10-min washes in tris-buffered saline tween-20, the membranes were incubated with the corresponding secondary antibody conjugated with HRP at room temperature for 1 h. Antibody binding was visualized using enhanced chemiluminescence ECL-Plus (Amersham Pharmacia, Piscataway, NJ, USA). Blots were quantified using analysis system (Quantity One, Hercules, CA, USA).

**Visualization of the autophagic degradation of mitochondria (mitophagy)**

When harvested, SH-SY5Y cells were fixed with 4 % paraformaldehyde (Amresco llc, Solon, OH, USA) at 4 °C for 10 min, washed with PBS and permeabilized with 0.5 % Triton X-100 for 2 min, then incubated with primary antibody, the monoclonal anti-LC3 antibody (1: 1000) overnight at 4 °C followed by the secondary antibody, a fluorescein isothiocyanate conjugated goat anti-rabbit antibody (1:60, Sigma-Aldrich) for 2 h at room temperature. Cells were observed by using a confocal microscope (Olympus, Tokyo, Japan) and then images were analyzed by Image-Pro Plus 6.0 software package (Bethesda, MD, USA) [20].

**Statistical analysis**

Statistical analyses were carried out using SPSS version 20.0 for Windows (IBM Corporation, New York, USA). All values were expressed as mean ± SD (n = 6 in each group). The statistical significance of differences between groups was evaluated using a one-way ANOVA followed by Fisher’s least significant difference t test, as a normal distribution in all groups was given. P value of <0.05 was considered as statistically significant.
Availability of supporting data

The data set supporting the results of this article is included within the article.

Abbreviations

ALP: autophagy lysosome pathway; ROS: reactive oxygen species; CHL: chole-
roquine; 3-MA: methyladenine; DA: dopaminergic; UPS: ubiquitin–proteasome
system; mTOR: mammalian target of rapamycin; iNpase: inositol monophos-
phatase; Rot: rotenone; MMP: mitochondrial membrane potential; DMSO:
dimethyl sulfoxide; PBS: phosphate buffered solution; H2DCFDA: 2,7–dichlo-
rofluorescein diacetate; DCF: dichlorofluorescein; LC3: microtubule associated
protein 1 light chain 3.

Authors’ contributions

LH and JH performed the immunostaining analysis and Western blotting
and drafted the manuscript. CH, GZ and XX performed the MTT assay and
flow cytometry manipulations. JL was involved in collecting data. NX and LL
designed the study and undertook the statistical analysis. LL and ZL contrib-
uted to manuscript revision. The corresponding author TW supervised the
whole study. All authors read and approved the final manuscript.

Author details

1 Department of Emergency, Central Hospital of Wuhan, Wuhan, Hubei, China. 2 Department of Neurology, Tongji Medical College, Union Hospital, Huazhong
University of Science and Technology, Wuhan, Hubei, China. 3 Division of Alco-
hol and Drug Abuse, Department of Psychiatry and Harvard NeuroDiscovery
Center, Harvard Medical School and Laboratory of Psychiatric Neurogenomics,
McLean Hospital, Belmont, MA, USA.

Acknowledgements

This work was supported by Grants 31171211 and 81473105 from the
National Natural Science Foundation of China (to TW), Grant 13BA010903
from National Key Technology Research and Development Program of the
Ministry of Science and Technology of China (to XS), Grant 81200983 from the
National Natural Science Foundation of China (to NX), Grant 81301082 from the
National Natural Science Foundation of China (to ISH), Grant 2012BA0909
from China Medical Foundation (to NX) and Grant 0203201343 from Hubei
Molecular Imaging Key Laboratory (to NX).

Compliance with ethical guidelines

The experiments described in this paper were approved by the Ethical
Committee on Animal Experimentation of Tongji Medical College, Huazhong
University of Science and Technology.

Competing interests

The authors declare that they have no competing interests.

Received: 1 August 2015 Accepted: 18 November 2015 Published online: 25 November 2015

References

1. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the
treatment of Parkinson disease (2009). Neurology. 2009;72(21 Suppl
4):S1–136.
2. Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome path-
way in neurodegeneration associated with Parkinson’s disease. Brain J
Neurol. 2008;131(Pt B):1969–78.
3. Shen YF, Tang Y, Zhang XJ, Huang XX, Le WD. Adaptive changes in
autophagy after UPS impairment in Parkinson’s disease. Acta Pharmacol
Sin. 2013;34(5):667–73.
4. Xiong N, Xiong J, Jia M, Liu L, Zhang X, Chen Z, Huang J, Zhang Z, Hou L,
Luo Z, et al. The role of autophagy in Parkinson’s disease: rotenone-based
modeling. Behav Brain Funct BBF. 2013;9:13.
5. Zheng Q, Li J, Wang X. Interplay between the ubiquitin-proteasome
system and autophagy in proteinopathies. Int J Physiol Pathophysiolog
Pharmacol. 2009;1(2):127–42.
6. Moshushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease
through cellular self-digestion. Nature. 2008;451(7182):1069–75.
7. Cheng Y, Ren X, Hatt WN, Yang JM. Therapeutic targeting of autophagy in
disease: biology and pharmacology. Pharmacol Rev. 2013;65(4):1162–97.
8. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A,
Adelli K, Agholme L, Agnello M, Agostinis P, Agurell-Ghiso JA, et al. Guide-
lines for the use and interpretation of assays for monitoring autophagy.
Autophagy. 2012;8(4):445–54.
9. Cai Z, Zhao B, Li K, Zhang L, Li C, Quai SH, Tan Y. Mammalian target of
rapamycin: a valid therapeutic target through the autophagy pathway for
Alzheimer’s disease? J Neurosci Res. 2012;90(6):1105–18.
10. Pan T, Kondo S, Zhu W, Xie X, Jankovic J, Le W. Neuroprotection of
rapamycin in lactacystin-induced neurodegeneration via autophagy
enhancement. Neurobiol Dis. 2008;32(1):16–25.
11. Pan T, Rawal P, Wu Y, Xie W, Jankovic J. Le W. Rapamycin protects against
rotenone-induced apoptosis through autophagy induction. Neurosci
ence. 2009;164(2):541–51.
12. Sarkassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway.
Curr Opin Cell Biol. 2005;17(6):596–603.
13. Motoy Shimada K, Ishiguro K, Hattori N. Lithium and autophagy. ACS
Chem Neurosci. 2014;5(6):434–42.
14. Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, Cook
LJ, Rubinsztein DC. Lithium induces autophagy by inhibiting inositol
monophosphatase. J Cell Biol. 2005;170(7):1101–11.
15. Sarkar S, Krishna G, Imarisio S, Saiki S, O’Kane CJ, Rubinsztein DC. A
rational mechanism for combination treatment of Huntington’s disease
using lithium and rapamycin. Hum Mol Genet. 2008;17(2):170–8.
16. Sarkar S, Rubinsztein DC. Inositol and IP3 levels regulate autophagy: biol-
ogy and therapeutic speculations. Autophagy. 2006;2(2):132–4.
17. Sobla-Adesakin O, Castillo-Quan JF, Rallis C, Bjedov I, Rogers I, Li L,
Martinez P, Khericha M, Cabecinna M, et al. Lithium suppresses Alzheimer’s
disease by inhibiting translation in an adult Drosophila model of
Alzheimer’s disease. Front Aging Neurosci. 2014;6:190.
18. Alalou B, Ozderem A, Allmer J, Genc K, Genc S. Lithium protects against
parakut neurotoxicity by NFR2 activation and miR-34a inhibition in SH-
SY5Y cells. Front Cell Neurosci. 2015;9:209.
19. Li XZ, Chen XP, Zhao K, Bai LM, Zhang H, Zhou XP. Therapeutic effects of
valproate combined with lithium carbonate on MPTP-induced parkinson-
ism in mice: possible mediation through enhanced autophagy. Int J
Neurosci. 2013;123(2):73–9.
20. Xiong N, Jia M, Chen C, Xiong J, Zhang Z, Huang J, Hou L, Yang H, Cao
X, Liang Z, et al. Potential autophagy enhancers attenuate rotenone-
induced toxicity in SH-SY5Y cells. Neurobiol Aging. 2013;34(5):899–907.
21. Yong Y, Ding H, Fan Z, Luo J, Ke ZJ. Lithium fails to protect dopaminergic
neurons in the 6-OHDA model of Parkinson’s disease. Neurochem Res.
2011;36(3):367–74.
22. Xiong N, Huang J, Chen C, Zhao Y, Zhang J, Jia M, Hou L, Yang H, Cao
X, Liang Z, et al. DR-3-n-butylnaphthalide, a natural antioxidant, protects
dopamine neurons in rotenone models for Parkinson’s disease. Neurobiol
Aging. 2012;33(8):1777–91.
23. Xiong N, Huang J, Zhang Z, Xiong J, Liu X, Jia M, Wang F, Chen C, Cao X,
Liang Z, et al. Stereotaxic infusion of rotenone: a reliable rodent model
for Parkinson’s disease. PLoS One. 2009;4(11):e7878.
24. Xiong N, Long X, Xiong J, Jia M, Chen C, Huang J, Ghoorah D, Kong X, Lin
Z, Wang T. Mitochondrial complex I inhibitor rotenone–induced toxicity
and its potential mechanisms in Parkinson’s disease models. Curr Rev
Toxicol. 2012;42(7):613–32.
25. Yoon YH, Cho KS, Hwang JI, Lee SJ, Choi JA, Koh YJ. Induction of lyso-
osomal dilatation, arrested autophagy, and cell death by chloroquine in
cultured ARPE-19 cells. Invest Ophthalmol Vis Sci. 2010;51(11):6038–7.
26. Holt SV, Wyspianska B, Randall KJ, James D, Foster JR, Wilkinson RW.
The development of an immunohistochemical method to detect the
autophagy-associated protein LC3-II in human tumor xenografts. Toxicol
Pathol. 2011;39(3):516–23.
27. D’Souza RT, Rajji TK, Mulsant BH, Pollock BG. Use of lithium in the
treatment of bipolar disorder in late-life. Curr Psychiatry Rep.
2011;13(6):488–92.
28. Chu CT, Chuang DM. Neuroprotective action of lithium in disor-
ders of the central nervous system. J Cent South Univ Med Sci.
2011;36(6):461–76.
29. Pasquali L, Longoni P, Isidoro C, Ruggieri S, Paparelli A, Fornai F. Autophagy, lithium, and amyotrophic lateral sclerosis. Muscle Nerve. 2009;40(2):173–94.
30. Wada A, Yokoo H, Yanagita T, Kobayashi H. Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J Pharmacol Sci. 2005;99(4):307–21.
31. Andreyev AV, Kushnareva YE, Starkov AA. Mitochondrial metabolism of reactive oxygen species. Biochem Biokhimia. 2005;70(2):200–14.
32. Lemasters JJ. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res. 2005;8(1):3–5.
33. Perier C, Bove J, Vila M, Przedborski S. The rotenone model of Parkinson’s disease. Trends Neurosci. 2003;26(7):345–6.
34. Ganguli A, Choudhury D, Datta S, Bhattacharya S, Chakrabart G. Inhibition of autophagy by chloroquine potentiates synergistically anti-cancer property of artemisinin by promoting ROS dependent apoptosis. Biochimie. 2014;107 Pt B:338–49.
35. Giordano S, Darley-Usmar V, Zhang J. Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol. 2014;2:82–90.
36. Sato M, Sato K. Degradation of paternal mitochondria by fertilization-triggered autophagy in C. elegans embryos. Science. 2011;334(6059):1141–4.
37. Lee J, Giordano S, Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J. 2012;441(2):523–40.
38. Erlich S, Alexandrovich A, Shohami E, Pinkas-Kramarski R. Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol Dis. 2007;26(1):86–93.
39. Scola G, Kim HK, Young LT, Salvador M, Andreazza AC. Lithium reduces the effects of rotenone-induced complex I dysfunction on DNA methylation and hydroxymethylation in rat cortical primary neurons. Psychopharmacology (Berl). 2014;231(2):4189–98.
40. Manji HK, Lenox RH. Lithium: a molecular transducer of mood-stabilization in the treatment of bipolar disorder. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 1998;19(3):161–6.
41. Sarkar S, Davies JE, Huang Z, Tunacliffie A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem. 2007;282(8):5641–52.
42. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature. 2002;417(6886):292–5.
43. Zhang JY, Peng C, Shi H, Wang S, Wang Q, Wang JZ. Inhibition of autophagy causes tau proteolysis by activating calpain in rat brain. J Alzheimers Dis. 2009;16(1):39–47.
44. Zhang Z, Cao X, Xiong N, Wang H, Huang J, Sun S, Liang Z, Wang T. DNA polymerase-beta is required for 1-methyl-4-phenylpyridinium-induced apoptotic death in neurons. Apoptosis Int J Program Cell Death. 2010;15(1):105–15.
45. Ma R, Xiong N, Huang C, Tang Q, Hu B, Xiang J, Li G. Erythropoietin protects PC12 cells from beta-amyloid(25-35)-induced apoptosis via PI3 K/ AKT signaling pathway. Neuropharmacology. 2009;56(6–7):1027–34.
46. Poort M, Zhang YZ, Kramer JA, Wells KS, Jones LJ, Hanzel DK, Lugade AG, Singer ML, Haugland RP. Analysis of mitochondrial morphology and function with novel fixable fluorescent stains. J Histochem Cytochem Off J Histochem Soc. 1996;44(12):1363–72.